The $17.00 cash consideration represents a 22% premium to the pre-announcement closing price on March 3, 2026, and a 10% premium to VWAP since that date. The CVR provides asymmetric upside if ampreloxetine is successfully monetized, but has no guaranteed value. Monitor the shareholder vote and HSR clearance timeline. The deal is not subject to a financing condition, reducing execution risk. The stock should trade near the cash consideration minus deal risk and time value of money.
Price Chart
Executive Summary
Theravance Biopharma (TBPH) entered into a definitive merger agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash plus one contingent value right (CVR) per share. The CVR entitles holders to 80% of net proceeds from any future monetization of ampreloxetine over ten years, plus a potential $50M milestone payment and 10% royalties on net sales. The all-cash deal values TBPH at approximately $929M equity value and is expected to close in H2 2026, subject to shareholder and regulatory approvals. The filing also includes employee communications (Item 7.01) and a press release (Item 8.01).
Key Financial Metrics
Key Facts
- Shareholders to receive $17.00 per share in cash plus one CVR per share
- CVR provides 80% of net proceeds from any ampreloxetine license/divestiture within 10 years post-close
- CVR also includes a $50M aggregate milestone payment upon first commercial sale in a Major Market
- CVR includes 10% royalty on net sales of ampreloxetine during the Royalty Term
- Equity value of the cash consideration is approximately $929 million
- Transaction expected to close in the second half of 2026
- Closing conditions include shareholder approval (two-thirds vote), HSR clearance, and no material adverse effect
- Parent has secured debt financing from OMERS Life Sciences; no financing condition to close
- Termination fee of $32.515M payable by either party in specified circumstances
- Company's Strategic Review Committee and Board unanimously approved the transaction
Financial Impact
Shareholders receive $17.00 per share in cash (~$929M equity value) plus CVR with potential additional value from ampreloxetine monetization (80% of net proceeds, $50M milestone, 10% royalties).
Risk Factors
- Shareholder approval may not be obtained
- Regulatory approvals (HSR) may be delayed or denied
- CVR may yield zero value if ampreloxetine is not monetized or commercialized
- Competing acquisition proposal could emerge and disrupt the deal
- Integration risks post-close could affect YUPELRI franchise performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078453 |
| Document: tm2619064d1_8k.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-3.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-1.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-2.htm | 0001104659-26-078453 |
| Document: 0001104659-26-078453-index-headers.html | 0001104659-26-078453 |
| Document: 0001104659-26-078453-index.html | 0001104659-26-078453 |
| Document: 0001104659-26-078453.txt | 0001104659-26-078453 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access